Cortexin
Research OnlyA Russian neuropeptide complex derived from porcine or bovine cerebral cortex, approved in Russia and CIS countries for neurological conditions. Contains low molecular weight polypeptides (1,000-10,000 Da) with proposed neurotrophic and neuroprotective properties. NOT approved by FDA, EMA, or other Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western validation.
Cortexinum · Polypeptide brain extract · Bovine brain cortex polypeptides
12 human studies
- Preclinical
- 57%
- Clinical
- 43%
Based on 28 cited sources
clinically demonstrated · very-low confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 65 (1A 28 / 1B 10 / 1C 9 / 1D 12 / 1E 6): ≥2 small Russian RCTs exist — a multicenter randomized controlled dose-finding study in chronic cerebral ischemia (n=189, PMID:30335070) and an RCT vs nootropil/ cerebrolysin in ischemic stroke (PMID:18193579), plus a controlled comparison vs encephabol in dyslexia (PMID:33728849) — but all are small, open-label, active-comparator, manufacturer-linked and best rated "some concerns" RoB with no high-confidence systematic review (1B). Cumulative human N is large (635-child multicenter study PMID:29652302) but heterogeneous, so precision is scored mid-band. Directness is high — actual IM clinical route, neurological populations, cognitive/neurological outcomes (1D 12). Substantial but single-group-dominated preclinical program (1E 6). Mechanism 55 (2A 20 / 2B 13 / 2C 13 / 2D 9): named-target measured binding to AMPA/kainate/mGluR/GABAA receptors (PMID:34260655) but Cortexin is an undefined polypeptide mixture, so no knockout/antagonist abolition and target attribution is weak; partial downstream mapping via β5-tubulin / 14-3-3 / creatine-kinase-B partners (PMID:30499504); monotonic dose-response across human (10 vs 20 mg, PMID:30335070) and animal (1 vs 3 mg/kg) in-vivo models. Plausibility 68 (3A 24 / 3B 21 / 3C 15 / 3D 8): mechanism → surrogate (SOD antioxidant markers PMID:30335070, EEG changes) established, surrogate → clinical benefit inferred; coherent with brain-peptide neuroprotection biology; same-class analogues (cerebrolysin, actovegin) show the effect head-to-head (PMID:34260655); deduction for broad multi-indication scope (stroke + cognitive + pediatric ADHD/dyslexia). Global Coverage 46 (4A 12 / 4B 8 / 4C 16 / 4D 10): research concentrated in one Russian cluster with little independent replication, multiple Russian institutions but essentially one country, ~28 diverse studies, registered in Russia/CIS (≥1 national regulator). Community Experience 54 (5A 9 / 5B 24 / 5C 9 / 5D 12): niche enthusiast discussion but >7 years of sustained Russian clinical use, sparse/mixed community signal, no recurring serious adverse signal. Effectiveness basis clinical (very-low confidence): Russian RCTs report dose-dependent neurological/cognitive improvement and a modest responder edge (73.3% vs 60% vs encephabol, PMID:33728849), roughly non-inferior to other neuroprotectors head-to-head, but estimates are weak, open-label and unreplicated outside CIS, so the magnitude is scored small-moderate with a Very Low flag.
Cortexin is a complex mixture of low molecular weight polypeptides (1,000-10,000 Da) extracted from porcine or bovine cerebral cortex. Unlike single-molecule peptides, Cortexin’s exact composition varies by batch. The synthetic tetrapeptide Cortagen (Ala-Glu-Asp-Pro) has been identified as a key active component through directed synthesis based on amino acid analysis of the natural preparation.
How It Works (Simplified)
Cortexin appears to act through multiple proposed pathways affecting neuronal function:
Proposed BDNF-like and NGF-like activity supporting neuronal survival, differentiation, and synaptic plasticity through interaction with brain-specific proteins.
Interacts with glutamate (AMPA, kainate, mGluR) and GABA receptors, potentially balancing excitatory and inhibitory neurotransmission.
Increases dopamine levels in the brain, supporting attention, memory consolidation, and cognitive processing functions.
Antioxidant effects and anti-apoptotic mechanisms may protect neurons from ischemic damage and oxidative stress.
Key Research: Kurkin DV et al. (Russia, 2021) demonstrated neuroprotective action of Cortexin in rat acute and chronic ischemia models. PMID:34260655
Important Limitations
- Exact peptide composition is not standardized and varies by batch
- Nearly all mechanistic studies from Russian institutions with manufacturer involvement
- No independent Western replication of proposed mechanisms
- Translation to human physiology largely unconfirmed outside Russian trials
- BBB penetration claimed but not rigorously characterized by Western standards
Based on Russian clinical protocols: Initial treatment phase with daily intramuscular injections. Some studies report early improvements in alertness and attention within the first week. Animal studies show early neurotrophic signaling activation.
PMID:29652302Russian protocols typically run 10-day treatment courses. Studies report progressive improvements in memory, concentration, and cognitive processing. Pediatric studies show attention improvements by week 3-4.
PMID:33728849Post-treatment observation period. Russian studies suggest effects may persist after discontinuation. Repeat courses may be administered after 3-6 month intervals per Russian protocols.
PMID:30335070Long-term outcomes poorly characterized. Russian practice involves repeated treatment courses. No controlled long-term safety or efficacy data available. Optimal treatment duration and frequency remain undefined.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Cerebrolysin
SynergisticBoth are brain-derived peptide complexes with neurotrophic properties. Cerebrolysin is porcine brain-derived while Cortexin is from cerebral cortex. Similar mechanisms targeting neuronal survival and plasticity. No direct clinical studies on combination.
Semax
CompatibleDifferent mechanisms of action (Cortexin complex neurotrophic support vs Semax ACTH-derived BDNF modulation). Both target cognitive enhancement through distinct routes. No known contraindications.
Selank
CompatibleNon-overlapping mechanisms. Cortexin focuses on neurotrophic support while Selank modulates anxiety and immune function. Theoretical complementary benefits for cognitive and mood support.
Dihexa
CompatibleBoth target cognitive enhancement but through different mechanisms. Dihexa is a synthetic HGF mimetic while Cortexin is a peptide complex. Limited data on interactions.
BPC-157
CompatibleBPC-157's tissue repair properties operate through different pathways than Cortexin's neurotrophic effects. No interaction studies available but mechanisms are distinct.
Thymosin-Alpha-1
CompatibleNon-overlapping mechanisms. Cortexin targets neuronal function while Thymosin Alpha-1 modulates immune function. May have complementary effects in neuroimmune contexts.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Cortexin
Related Peptides
Alixorexton
ALKS 2680 · ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Cerluten
Brain cytamin · Cerebral peptides · A-5 brain peptides
A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Dihexa
PNB-0408 · N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
DSIP
Delta Sleep Inducing Peptide · Delta Sleep-Inducing Peptide · WAGGDASGE
A nonapeptide discovered in 1977 that was initially thought to induce delta wave sleep. Research has shown broader neuromodulatory effects including stress-protection and analgesia, though its role as an endogenous sleep factor remains controversial.
N-Acetyl Selank Amidate
NA-Selank · N-Acetyl Selank · Acetyl-Selank-Amidate +1
A modified version of Selank with N-terminal acetylation and C-terminal amidation designed to enhance stability and bioavailability. While the parent compound Selank is approved in Russia, N-Acetyl Selank Amidate has no independent clinical research and relies entirely on extrapolated claims from Selank studies.
N-Acetyl Semax Amidate
NA-Semax · N-Acetyl Semax · Acetyl-Semax-Amidate +1
A chemically modified version of Semax with N-terminal acetylation and C-terminal amidation designed to enhance peptide stability. While parent Semax is approved in Russia for nootropic and neuroprotective applications, this specific modification has no independent clinical research.